Telmi 40

Quick links to important sections

Telmi 40

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Telmi 40

Quick Facts

  • Active Ingredient: Telmisartan
  • Drug Class: Angiotensin II Receptor Blocker (ARB)
  • Primary Use: Management of high blood pressure (hypertension)
  • Common Strengths: Available as 20 mg, 40 mg, and 80 mg oral tablets

Telmi 40 is a brand name for a medication containing the active substance telmisartan, an angiotensin II receptor blocker (ARB). This class of medication is primarily used to treat essential hypertension (high blood pressure). Controlling high blood pressure is critical for reducing the long-term risk of serious cardiovascular events, such as stroke and heart attack.

In addition to treating hypertension, telmisartan is also indicated for reducing the risk of a heart attack, stroke, or death from cardiovascular causes in adults who are 55 years of age or older and at high risk of developing these major events. This high-risk group includes patients with a history of coronary artery disease, peripheral arterial disease, stroke, or high-risk diabetes with evidence of end-organ damage.

Mechanism of Action

Telmisartan works by selectively blocking the binding of a natural substance in the body called angiotensin II to a specific receptor type (the AT1 receptor) found on blood vessel walls. Angiotensin II normally causes blood vessels to constrict or tighten. By blocking its effects, telmisartan allows the blood vessels to relax, which lowers blood pressure and permits blood to flow more smoothly. This mechanism helps the heart pump more efficiently and decreases the workload on the cardiovascular system.

What side effects are possible with Telmi 40?

Possible Side Effects and Safety Information

The safety profile of Telmisartan (Telmi 40), an Angiotensin II Receptor Blocker (ARB), is established through formal regulatory documentation, classifying potential adverse reactions by both frequency and the specific body system affected.


Official Adverse Reaction Classification

Adverse reactions are formally grouped by how often they appear in clinical data:

  • Common: Hypotension (low blood pressure), especially in patients treated for cardiovascular risk reduction.
  • Uncommon: Effects spanning multiple body systems, including upper respiratory tract and urinary tract infections, anaemia, hyperkalaemia, depression, syncope, vertigo, cough, diarrhea, abdominal pain, back pain, muscle spasms, and renal impairment (including acute renal failure).
  • Rare: Sepsis (including fatal outcome), eosinophilia, thrombocytopenia, hypersensitivity, Angioedema (swelling of the face or throat, including fatal outcome), hypoglycemia in diabetic patients, and abnormal hepatic function.
  • Very Rare: Interstitial lung disease.

Serious Safety Considerations

Regulatory documents highlight severe reactions, noted for their clinical importance despite their rare occurrence, such as Sepsis, Anaphylactic reaction, and Angioedema. Furthermore, the drug is associated with potential Fetal Toxicity and Morbidity if used during the second and third trimesters of pregnancy.


Population-Specific Constraints

The official labeling defines specific safety limitations for certain patient groups. Use is contraindicated during the second and third trimesters of pregnancy and in individuals with severe hepatic impairment, cholestasis, or biliary obstructive disorders. Patients with volume or salt depletion may experience symptomatic hypotension, particularly after the initial dose. The co-administration of Telmisartan with aliskiren is contraindicated in patients with diabetes.

Overdose and Emergency Response

Overdose and when to seek help — Official Regulatory Information for Telmi 40

Overdose Scope

Domain Official Regulatory Statement
Documented Manifestations: The most prominent sign of overdose is hypotension (low blood pressure), which may be accompanied by alterations in heart rate, specifically tachycardia (rapid) or bradycardia (slow).
Physiological Systems Affected: Primarily the cardiovascular system (blood pressure and heart rate). Monitoring requirements indicate potential effects on serum electrolytes and renal function.
Emergency Action Required: Seek emergency medical attention or contact a Poison Control center immediately in case of a suspected overdose.

Overdose Classifications (High-Level)

Classification Official Regulatory Statement
Severity Classification: The primary risk involves severe hypotension, which may progress to circulatory shock.
Antidote Status: No specific antidote is known for Telmisartan.
Treatment Constraints: Telmisartan is not removed by hemodialysis, thus management is confined to symptomatic and supportive care.

Connection to the Overall Overdose Profile

Regulatory documents define the Telmisartan overdose profile as an extreme exaggeration of its blood-pressure-lowering effect, manifesting as clinically significant hypotension. This condition is classified as a serious risk that mandates immediate contact with emergency medical services. Management is strictly supportive, including placing the patient in the supine position and administering intravenous saline if necessary to treat symptomatic hypotension.

Therapeutic Uses of Telmi 40

What Telmi 40 Treats: Main Uses and Benefits

Telmi 40 is commonly used across domains where additional symptomatic support is needed, and is relevant in situations where symptoms form part of conditions marked by increased physiological stress. Telmisartan is authorized for two core therapeutic purposes: the treatment of high blood pressure and the prevention of cardiovascular events.

Therapeutic Applications

The medicine is relevant in clinical settings for managing essential hypertension in adults, and for reducing the risk of major cardiovascular events in patients with a history or factors placing them in a high-risk group. It helps address symptoms related to heightened physiological activity and systemic imbalance. The use of this medicine helps maintain a sense of stability when symptoms are more noticeable.

It is applied during phases when symptoms become more noticeable and supportive relief is needed, assisting with symptom clusters that may create noticeable functional strain, and supports general well-being during symptomatic phases.

Quick Fact: Used for Managing Hypertension Symptoms (e.g., those related to increased physiological activity).

Regulatory References

  1. European Medicines Agency overview

Eligibility and Restrictions for Use

Who can and cannot use Telmi 40?

This section describes the officially documented population eligibility rules for Telmi 40 (telmisartan) as established in government regulatory documents.

Contraindicated Populations

Telmi 40 is contraindicated (must not be used) in patients with known hypersensitivity to the medicine or its excipients. Absolute prohibition also applies to women in the second and third trimesters of pregnancy. Additionally, the medicine is contraindicated in patients with severe hepatic impairment or biliary obstructive disorders, including cholestasis. Concomitant use with aliskiren is prohibited in patients with diabetes mellitus or moderate-to-severe renal impairment.

Age-Related and Conditional Eligibility

Use is approved for the adult population and no dose adjustment is necessary for geriatric patients. However, safety and efficacy have not been established in children and adolescents (below 18 years), and use in this age group is not recommended. Use is also not recommended for women in the first trimester of pregnancy or for those who are breastfeeding. In patients with mild to moderate hepatic impairment, the dosage is restricted and must not exceed 40 mg daily.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Telmisartan's interaction profile is characterized by pharmacodynamic augmentations and specific pharmacokinetic constraints documented in regulatory labeling.

Official Interaction Statements

Classification Interacting Entity Official Interaction Statement
Contraindicated Aliskiren Co-administration is contraindicated in patients with diabetes mellitus or moderate-to-severe renal impairment (GFR < 60 mL/min/1.73 m^2) due to increased risk of hyperkalemia and renal dysfunction.
Pharmacodynamic ACE-inhibitors or other ARBs Dual blockade of the Renin-Angiotensin-Aldosterone System (RAAS) is not recommended as it increases the risk of hyperkalemia, hypotension, and renal function changes.
Pharmacodynamic Potassium-sparing diuretics, Potassium supplements, Salt substitutes Concurrent use elevates the risk of hyperkalemia due to additive effects on serum potassium levels.
Pharmacodynamic Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) NSAIDs may reduce the blood pressure-lowering effect of Telmisartan and increase the risk of renal function deterioration.
Pharmacokinetic Digoxin Telmisartan, acting as an intestinal P-glycoprotein (P-gp) inhibitor, significantly increases Digoxin plasma concentrations (C max by up to 50%), necessitating monitoring.
Other Lithium Co-administration may increase serum Lithium concentrations and the risk of toxicity.
Substance Alcohol (Ethanol) May have an additive effect on lowering blood pressure, increasing the risk of hypotension.

Population-Specific Constraints

Telmisartan is contraindicated in patients with severe hepatic impairment or biliary obstructive disorders because reduced biliary clearance is expected to increase systemic exposure. The dual RAAS blockade constraints concerning Aliskiren are strictly tied to the presence of diabetes or moderate-to-severe renal impairment.

Mechanism of Action

Telmi 40 (telmisartan) is an angiotensin II receptor blocker (ARB) that acts through two primary and distinct mechanistic pathways, targeting hormone-mediated signaling and metabolic regulation to exert its molecular and biochemical effects.

Angiotensin II Type 1 (AT1) Receptor Blockade

This domain involves acting as a highly selective competitive antagonist at the AT1 receptor site. By blocking the binding of the signaling hormone, angiotensin II, Telmi 40 prevents downstream cascades that cause blood vessel constriction and stimulate the release of fluid-retaining hormones like aldosterone. This mechanism modifies early molecular steps to influence the regulation of vascular tone and fluid balance, resulting in physiological adjustments of vascular resistance.


PPAR-gamma Partial Agonism

Telmi 40 also engages secondary, non-RAAS mechanisms by acting as a partial agonist on the nuclear hormone receptor Peroxisome Proliferator-Activated Receptor-gamma (PPAR-gamma). This involvement modulates pathways mediated by the PPAR-gamma receptor, influencing related metabolic and inflammatory signaling cascades. This dual mechanism influences the regulation of physiological processes by modulating the signaling pathways involved in glucose and lipid metabolism, in addition to its primary vascular effects.

Dosage and Administration Information

How to Use Telmi 40: Official Administration Guidelines

Telmi 40 (telmisartan) is approved for once-daily oral administration as a tablet for the long-term management of its indications. The medication is designed to be administered with or without food, swallowed with a small amount of liquid. Achieving the full blood pressure-lowering effect typically requires four weeks of continuous use.

Standardized Dosing and Schedules

Administration is scheduled once daily for all approved uses. For treating high blood pressure, the standard starting dose is 40 mg once daily, with the ability to adjust the dose within a maintenance range of 20 mg to 80 mg, up to a maximum of 80 mg per day. For the reduction of cardiovascular events, the labeled dose is fixed at 80 mg once daily.

Usage Constraint Official Administration Rule
Tablet Handling The tablet must be taken immediately after removal from its blister packaging due to its sensitivity to moisture.
Missed Dose If a dose is missed, patients should not take a double dose to compensate but should resume the scheduled administration at the usual time.

Population-Specific Use Limits

Official instructions provide specific dose limits for certain patient groups. For individuals diagnosed with mild-to-moderate liver impairment, the total daily dose is restricted and should not exceed 40 mg. For patients over 65, no initial dose adjustment is typically necessary based on age alone.

Recent Clinical Evidence

Telmi 40: Recent Clinical Evidence

Clinical evidence for Telmi 40 (telmisartan 40 mg) focuses on its approved use for managing essential hypertension (high blood pressure) and reducing major cardiovascular events in high-risk adults.


Efficacy in Blood Pressure Management

Studies, including practice-based clinical trials, have consistently shown that telmisartan contributes to a statistically significant reduction in both systolic and diastolic blood pressure (BP). In patients whose BP was not adequately controlled by a starting dose of 40 mg, titration to 80 mg was shown to lead to a further average reduction in BP. The majority of the anti-hypertensive effect is typically observed within two weeks, with the maximum reduction often attained within four weeks of initiating treatment.

Reduction of Cardiovascular Risk

Research has specifically examined the role of telmisartan in cardiovascular (CV) protection. In large-scale, controlled trials involving patients aged 55 or older who have established atherosclerotic disease or high-risk type 2 diabetes, the medication was shown to be associated with a reduction in the risk of myocardial infarction (heart attack), stroke, and death from CV causes.


Comparative and Metabolic Findings

Subgroup analyses and meta-analyses comparing telmisartan to other Angiotensin II Receptor Blockers (ARBs), such as losartan, have explored differences in blood pressure-lowering potential, with some data suggesting better reduction in both systolic and diastolic BP for telmisartan in certain populations.

Further research continues to investigate a unique property of telmisartan: its ability to partially interact with the Peroxisome Proliferator-Activated Receptor-gamma (PPAR-gamma) pathway. This interaction is the subject of ongoing studies exploring its potential association with metabolic benefits, such as the regulation of glucose and lipid parameters.

Frequently Asked Questions (FAQ)

Common questions about Telmi 40 (FAQ)

Q: Does Telmi 40 affect kidney function long-term?

Official safety information indicates that Telmi 40 may cause renal impairment or, in rare cases, acute renal failure. This potential risk is noted to be higher when the drug is taken with certain other medicines, such as NSAIDs (non-steroidal anti-inflammatory drugs) or other drugs that block the RAAS system.


Q: What is the main difference between Telmi 40 and an ACE inhibitor like lisinopril?

Telmi 40 is classified as an Angiotensin II Receptor Blocker (ARB), which means it targets the body's blood pressure control system differently than an ACE inhibitor. Regulatory documents generally do not recommend using both an ARB and an ACE inhibitor together due to potential safety risks.


Q: Does Telmi 40 have any effect on blood sugar levels?

According to regulatory safety profiles, a rare adverse reaction that has been noted is hypoglycemia, which is low blood sugar. This effect has specifically been reported in diabetic patients who are using this medication.


Q: Is Telmi 40 safe for older adults (seniors) with multiple health conditions?

Official documentation states that generally no initial dose adjustment is required based on age alone for individuals over 65. However, specific conditions like severe liver or kidney impairment have dosage restrictions or may be contraindicated for use, regardless of the patient's age.


Q: Are there any inactive ingredients in Telmi 40 that might cause an allergic reaction?

Yes, hypersensitivity—or a serious allergic reaction—to the active substance or its excipients is listed as a contraindication in the official product information. Excipients are the inactive ingredients used to make the tablet.


Q: Is Telmi 40 generally considered safe to use for people who have diabetes?

Regulatory warnings state that Telmi 40 is contraindicated when used in combination with the medicine aliskiren if the patient has diabetes. This specific drug combination carries an increased risk of high potassium levels and kidney dysfunction.


Q: Does Telmi 40 cause changes in cholesterol levels?

Studies have investigated the drug's activity with the PPAR-gamma pathway, which is noted to be involved in the regulation of both glucose and lipid parameters. This unique mechanism is the subject of ongoing research.


Q: Are there any general expectations for how long treatment with Telmi 40 may last?

Telmi 40 is officially approved for the long-term management of its indications, which include high blood pressure and the reduction of cardiovascular risk. The duration of treatment is determined by the prescribing healthcare provider based on the condition being managed.


Q: What types of potassium-rich foods might interact with Telmi 40?

Regulatory warnings highlight that co-administration with potassium supplements or salt substitutes may increase the risk of high potassium levels (hyperkalemia). These warnings focus specifically on high-potassium products and supplements, rather than general food consumption.


Q: Is there official guidance on what to do if blood pressure drops too low while using Telmi 40?

The official label identifies the potential for symptomatic hypotension (low blood pressure that causes symptoms) to occur, particularly when treatment is initiated. Regulatory documents state that managing severe hypotension may require supporting medical measures, as assessed by a healthcare professional.


Q: What is the average duration of action for Telmi 40 in the body?

The active substance in Telmi 40 is designed to stay active in the body for an extended period, which supports its once-daily administration schedule. Official documentation reports that the drug has a long elimination half-life of approximately 20 to 24 hours.


Q: Does Telmi 40 cause a persistent dry cough like some other blood pressure medicines?

Official safety profiles list a general cough as an uncommon adverse reaction associated with this medication. However, regulatory documentation does not specify the cough as being persistent or dry.


Q: Is Telmi 40 often taken in combination with a diuretic (water pill)?

Yes, the medication is authorized for use in combination with other blood pressure treatments. This includes use alongside other antihypertensive agents, such as a thiazide diuretic (often referred to as a water pill), in patients who need additional blood pressure control.


Q: What food or drinks should be limited while taking Telmi 40?

Official warnings note that using alcohol concurrently may increase the blood pressure-lowering effect of the medicine. Co-use of salt substitutes that contain potassium is also highlighted in regulatory documents as a potential concern.


Q: Are there research studies comparing Telmi 40's cardiovascular benefits to other drug classes?

Clinical evidence published in official documents primarily details comparisons of Telmi 40 to a placebo and to other drugs in the ARB class (Angiotensin II Receptor Blockers). The official documents confirm that research has examined the drug's benefits for reducing cardiovascular risk.


Q: Can Telmi 40 cause changes in vision or blurry sight?

Official regulatory documentation includes visual disturbance in the safety profile, listing it as an uncommon adverse reaction associated with the use of this medication.


Q: Is Telmi 40 known to be habit-forming or addictive?

Official product labeling includes a specific section on dependence and confirms that Telmi 40 is not associated with the potential for abuse or the development of physical dependence.


Q: Can Telmi 40 affect heart rate or cause palpitations?

Official safety documentation lists changes in heart rate as potential adverse reactions. Bradycardia (slow heart rate) is noted as an uncommon reaction, and tachycardia (fast heart rate) is noted as a rare reaction.


Q: Are there different brand names for the Telmi 40 active ingredient?

Yes, the active ingredient in Telmi 40, which is telmisartan, is recognized and sold under various other brand names internationally.


Q: What is the significance of the number '40' in the drug name Telmi 40?

The number 40 in the drug name refers to the dosage strength of the active ingredient, telmisartan, in milligrams (mg). This 40 mg strength is often cited in official documentation as the standard starting dose for treating high blood pressure.

How should Telmi 40 be stored and disposed of?

Official Storage and Disposal Instructions

Telmisartan 40 mg tablets must be stored according to strict environmental conditions to maintain stability, as defined in official regulatory labeling.

Storage Requirement Condition
Temperature Store at controlled room temperature, 20 C to 25 C (68 F to 77 F).
Protection Keep the tablets in the original sealed blister pack to protect against moisture, as the product is hygroscopic.
Child Safety The medicine must be stored out of the sight and reach of children.

The tablets should not be removed from the blister until immediately prior to use. Disposal of any unused or expired product must be conducted strictly in accordance with local regulations and environmental legislation. Do not flush the tablets down a toilet or pour them down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Telmi 40 found in:

A-Z Index: